Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNYR vs ABUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABUS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

ABUS Overall Winner 6-Pillar Tally: SNYR 2 – 4 ABUS Matrix Metrics: SNYR 4 – 6 ABUS

As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin).

  • Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (80.1% vs. -10.3% operating margin) and revenue trajectory (-43.5% vs. -32.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNYR vs ABUS
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14
ABUS NASDAQ Head-to-Head Winner
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.02
-1.23% 1D
Market Cap $623.9M
TTM Revenue $181M
Forward P/E 10.2x
Beta / 30D Vol 1.04β · 48% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 68.0 Mom 53.7
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $4.02 · SMA50: $4.35

6-Pillar Scorecard Institutional Category Breakdown (SNYR 2 – 4 ABUS)

Columns: Metric · SNYR · ABUS
1. Valuation Multiples SNYR
Forward P/E 0.6x 10.2x
Trailing P/E 0.6x 3.6x
PEG Ratio N/M N/M
EV / Revenue 0.1x 2.0x
2. Growth & Scale ABUS
Revenue Growth (YoY) -32.8% -43.5%
Earnings Growth (YoY) -90.6% +0.0%
TTM Revenue (USD) $28M $181M
Market Cap $4.1M $623.9M
3. Profitability & Quality ABUS
Gross Margin 65.4% 91.9%
Operating Margin -10.3% 80.1%
Net Profit Margin -57.0% 121.2%
Return on Equity (ROE) -361.1% 269.6%
4. Balance Sheet & Cash Flow ABUS
Cash Generation (TTM) -$3.8M $221M
Cash Flow Margin -13.7% N/A
Net Cash / Leverage -361.1% ROE $264M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABUS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 133.2% (18th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 75.7% of Rev ($21M) 11.8% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Distribution Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNYR (4) vs ABUS (6)
Institutional Metric SNYR ABUS Criterion Row Edge
Market Capitalization
Scale
$4.1M $623.9M Larger Scale ABUS
Trailing P/E Ratio
Valuation
0.6x 3.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
0.6x 10.2x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
-32.8% -43.5% Higher Growth SNYR
Operating Margin (TTM)
Profitability
-10.3% 80.1% Higher Margin ABUS
Net Profit Margin
Profitability
-57.0% 121.2% Higher Margin ABUS
Return on Equity (ROE)
Capital Efficiency
-361.1% 269.6% Higher ROE ABUS
52-Week Range Position
Momentum
1% ($0–$3) 27% ($4–$5) Stronger Trend ABUS
Beta / 30D Volatility
Risk Regime
-0.86β · 868% Vol 1.04β · 48% Vol Lower Realized Risk ABUS
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 43.4 / 100 (HOLD) Higher Composite SNYR
Trailing 12M Revenue (USD)
Operating Scale
$28M $181M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.4% 91.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.8M (-361.1% ROE) $221M ($264M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABUS +21.03 pp
SNYR: -16.28% · ABUS: +4.75%
3M Horizon ABUS +71.09 pp
SNYR: -56.64% · ABUS: +14.45%
6M Horizon ABUS +112.49 pp
SNYR: -93.2% · ABUS: +19.29%
1Y Horizon ABUS +114.87 pp
SNYR: -96.13% · ABUS: +18.74%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SNYR Revenue ABUS Revenue SNYR Op. Margin ABUS Op. Margin Margin Leader
FY2018 $30M $10M -14.5% -1510.2% SNYR
FY2019 $30M $10M -27.1% -2394.0% SNYR
FY2020 N/A $10M N/A -836.1% ABUS
FY2021 N/A $10M N/A -669.1% ABUS
FY2022 N/A $40M N/A -167.8% ABUS
FY2023 $40M $20M 25.3% -430.5% SNYR
FY2024 $30M $10M 16.7% -1236.7% SNYR
FY2025 $30M $10M -27.8% -271.0% SNYR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABUS CONSOLIDATION
96d in phase · OBV ACCUMULATION
Current IV 133.2%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ABUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published
ABUS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $623.9M market capitalization and 80.1% operating margin.
OpEx & R&D Reinvestment 11.8% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ SNYR vs ABUS Key Questions & Quantitative Answers

As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNYR carries a Unified Composite Score of 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin). Composite vs. Pillar Nuance: While SNYR currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (80.1% vs. -10.3% operating margin) and revenue trajectory (-43.5% vs. -32.8% YoY).

ABUS leads the Growth & Scale pillar: SNYR posts -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin), compared with ABUS at -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SNYR cumulative revenue shifted +0.0% while ABUS shifted +0.0%. In operating R&D and SG&A reinvestment, SNYR deploys 75.7% of Rev ($21M) (0 90-day corporate R&D disclosures) versus 11.8% of Rev ($21M) (0 disclosures) for ABUS.

SNYR screens cheaper on headline valuation multiples. SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin), whereas ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNYR (-361.1% ROE) versus ABUS (269.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk). By comparison, ABUS carries 133.2% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.